Syncona Ltd announced that it has committed $42.5 million (£33.5 million) to a $170 million (£134 million) Series B financing of its portfolio company Beacon Therapeutics, a leading ophthalmic gene therapy company
All posts tagged Syncona Ltd
Syncona to sell Clade Therapeutics to Century Therapeutics for $45 million
LONDON: Syncona Ltd has signed an agreement for the sale of its portfolio company Clade Therapeutics to Century Therapeutics for $45 million. Century is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies. Syncona committed $30 million to Clade in August 2021 alongside a syndicate of specialist investors as part of a $87…
Syncona Ltd to acquire all shares of Freeline Therapeutics at the rate of $6.5/share
LONDON, UK: Syncona Ltd’s newly established portfolio company has entered into an agreement with Freeline Therapeutics Holdings plc to acquire all of the shares of Freeline that Syncona does not currently own in an all-cash transaction. Syncona currently owns 49.7% of Freeline. Under the agreement, a newly established Syncona portfolio company will acquire Freeline for…
Martin Murphy to step down as Chair of Syncona Investment Management Limited
LONDON, UK: Syncona Ltd announced that Martin Murphy is stepping down as Chair of Syncona Investment Management Limited (SIML) with Chris Hollowood taking on the role of Interim Chair and Chief Executive Officer (CEO) of SIML. Martin will continue to represent Syncona on the Boards of Autolus, Anaveon and Clade. Martin co-founded Syncona with the…
Kemal Malik appointed non-executive director at Syncona Ltd
LONDON: Syncona Ltd, a leading healthcare company, announces the appointment of Dr Kemal Malik as a Non-Executive Director with immediate effect. Kemal has 30 years of experience in global pharmaceutical research and development and has been responsible for bringing many innovative medicines to commercialisation. Kemal has spent much of his recent career at Bayer where,…